dexbrompheniramine

Trade name: disomer

Small moleculeapproved

Approved

Oct 18, 1963

DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes. — NCATS

Clinical trial activity

1 trials · 11 clinical orgs · 6 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jul 1, 2007 (NCT00509275)

Timeline

1950s

Jun 1, 1959
Schering-Plough — First NDA Organization
Jun 1, 1959
Schering-Plough — NDA Organization

1960s

Oct 18, 1963
Earliest FDA Approval
Oct 18, 1963
Schering-Plough — Marketing Organization

1980s

Jul 8, 1986
Schering — Marketing Organization
Jan 22, 1987
Copley Pharmaceuticals — Marketing Organization

1990s

Sep 30, 1991
Sandoz — Marketing Organization

2000s

Jan 1, 2007
Earliest Phase 1 Sponsor(trial)

2010s

Feb 27, 2013
Avanthi Pharma — Marketing Organization

Indications

Approved for

Studied for

Tinea Pedis · Phase 1

Mechanism of action

Histamine H1 receptorANTAGONIST
HRH1 antagonist
- Histamine H1 receptor (HRH1) ↗

Combination products

disophrol
with pseudoephedrine
Also known as brompheril, disobrom, drixoral
drixoral plus
with acetaminophen, pseudoephedrine

Approval history

approvedOct 18, 1963

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CC[C@@H](c1ccc(Br)cc1)c1ccccn1

Mol. weight: 319.25 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Discontinued

Oral

Yes

Parenteral

Topical

Sources

Also known as

3-(4-bromophenyl)- n,n-dimethyl- 3-pyridin-2-yl-propan-1-amine
3-(4-bromophenyl)- n,n-dimethyl- 3-pyridin-2-yl-propan-1-amine
(+)-brompheniramine
(+)-brompheniramine maleate
(+)-brompheniramine maleate
(+)-brompheniraminum
(+)-brompheniraminum
d-brompheniramine
d-brompheniramine
d-brompheniramine
desbrofeniramina
desbrofeniramina
dexbromfeniramina
dexbromfeniramina
dexbrompheniramin
dexbrompheniramin
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbrompheniramine
dexbromphéniramine
dexbromphéniramine
dexbrompheniramine fumarate
dexbrompheniramine fumarate
dexbrompheniramine maleate
dexbrompheniramine maleate
dexbrompheniramine maleate
dexbrompheniramine maleate
dexbrompheniramine maleate
dexbrompheniraminum
dexbrompheniraminum
disophrol
(+)-parabromdylamine
(+)-parabromdylamine
(r)-3-(4-bromophenyl)-3-(2-pyridyl)propyldimethylamine
(r)-3-(4-bromophenyl)-3-(2-pyridyl)propyldimethylamine
(s)-brompheniramine
(s)-brompheniramine
(s)-(+)-brompheniramine
(s)-(+)-brompheniramine
w0027
w0027

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00509275	Phase 1	Jul 1, 2007	Dermatology Specialists, Louisville, GlaxoSmithKline, International Dermatology Research Inc., NewLab Clinical Research, Skin and Cancer Foundation, Carlton, Australia, South East Dermatology, South East Dermatology, Carina QLD 4152, Australia, St. George Hospital, Kogarah, Stiefel Laboratories, The Skin Centre, Benowa, Australia, University of Adelaide, University of Cincinnati

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (11)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Dermatology Specialists, Louisville	Academic/Hospital	1	0	1	2007
GlaxoSmithKline	For profit	1	0	1	2007
International Dermatology Research Inc.	For profit	1	0	1	2007
NewLab Clinical Research	Academic/Hospital	1	0	1	2007
Skin and Cancer Foundation, Carlton, Australia	Academic/Hospital	1	0	1	2007
South East Dermatology, South East Dermatology, Carina QLD 4152, Australia	Academic/Hospital	1	0	1	2007
St. George Hospital, Kogarah	Academic/Hospital	1	0	1	2007
Stiefel Laboratories	For profit	1	1	1	2007
The Skin Centre, Benowa, Australia	Academic/Hospital	1	0	1	2007
University of Adelaide	Academic/Hospital	1	0	1	2007
University of Cincinnati	Academic/Hospital	1	0	1	2007

11 organizations

Page 1 / 1

Marketing (8)

Organization	Org type	Relationship	Date
Avanthi Pharma	For profit	MKTG	Feb 27, 2013
Copley Pharmaceuticals	For profit	MKTG	Jan 22, 1987
Dow Chemical	For profit	MKTG	—
Sandoz	For profit	MKTG	Sep 30, 1991
Schering	For profit	MKTG	Jul 8, 1986
Schering	For profit	NDA2	—
Schering-Plough	For profit	NDA	Jun 1, 1959
Schering-Plough	For profit	MKTG	Oct 18, 1963